Trials / Unknown
UnknownNCT01436695
Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Epicall LTD · Industry
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Not accepted
Summary
Epilepsy is a syndrome of episodic brain dysfunction characterized by recurrent seemingly unpredictable spontaneous seizures. The occurrence of the seizure in patients without any forewarning is the most debilitating aspect of the disease. The Epicall system is intended for early detection of seizure related life threatening events by monitoring per-seizures biomarkers. The system is based on a sticker placed on the side of the face. The external sticker incorporates EOG (electrooculograph electrode) and PPG (photoplethysmograph electrode) sensors for continuous monitoring of: 1. Heart Rate (base line, increase, decrease, asystole). 2. Extra ocular eye movement (blinking, eye deviation, roving eye movements).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Epicall | The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers. |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-06-01
- First posted
- 2011-09-20
- Last updated
- 2011-09-20
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01436695. Inclusion in this directory is not an endorsement.